

# Cancer of the Uterine Cervix

Effective Date: January, 2021



## Background

Cancer of the uterine cervix is the third most common cancer of the female genital tract (twelfth most common cancer overall, among women). It accounts for 1.6% of all cancers in women and is the sixteenth leading cause of death due to all cancers in women <sup>1</sup>. In Alberta, there were 135 new cases and 35 deaths in 2012 <sup>2</sup>. The five-year survival rate for cervical cancer is about 71%, as most cases are detected early due to the use of Pap tests <sup>3</sup>. Most cases are found in women under the age of 50 years <sup>4</sup>.

There are several histological types of cervical cancer. These include squamous cell (epidermoid) carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinomas, and primary sarcomas of the cervix. Staging of cervical cancer is based on the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) <sup>5</sup>. The classification system was updated in 2010 <sup>6</sup>. A detailed description of this staging system can be found in the Appendix.

## Guideline Questions

1. What should be considered during the staging of patients so that the appropriate primary treatment is given?
2. Does radiotherapy following surgery, versus surgery alone, increase survival rates among patients with early stage disease?
3. What are the appropriate indications for adjuvant therapy either after primary surgery or radiotherapy?
4. Is chemoradiotherapy more effective than radiotherapy alone in increasing survival? If so, what is the optimal platinum-containing chemotherapy regimen?

## Search Strategy

Entries to the Medline, EMBASE, and Cochrane databases and clinical practice guideline databases were searched for evidence relevant to this topic. Search terms included: *cervix* or *cervical* or *uterine cervix* AND *carcinoma* or *neoplasm* or *cancer*, with limits of human studies only. Among the studies returned by the search, those that did not report survival or toxicity outcomes and those that had fewer than 100 patients per treatment arm were excluded.

Guidelines reviewed include the following: the National Comprehensive Cancer Network (NCCN) guidelines <sup>7</sup>, the European Society for Medical Oncology (ESMO) guidelines <sup>8</sup>, the BC Cancer Agency (BCCA) guidelines <sup>9</sup>, and Cancer Care Ontario (CCO) Program in Evidence-Based Care guidelines <sup>10-12</sup> Tom Baker Cancer Centre <sup>13</sup> and the American Society of Clinical Oncology (ASCO) <sup>3</sup>. An effort was made to either adapt or adopt the most appropriate guidelines from other sources so that work wasn't duplicated. An evidence based perspective was used to draft proposals. Where evidence was weak a guideline was developed using pragmatic consensus within the group.

The guideline was originally developed in 2009 and then updated in 2011, 2012, 2013, 2015 and again in 2020. The literature was reviewed prior to each update, using the search strategy described above. The 2012 and 2013 reviews included a total of 21 studies and 2 studies, respectively. The 2015 review focused on neoadjuvant chemotherapy, upfront lymph node debulking, sentinel lymph node biopsy (SLNB) and trachelectomy and included a total of 21 studies. Following a review of the evidence by the Alberta Gynecologic Oncology Team, relevant literature was added to the discussion section. In 2020 the review focused on FIGO staging and recommendation for cervical examination and included total of 7 studies.

## Target Population

The recommendations outlined in this guideline apply to adults over the age of 18 years with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. Rare histologies will be treated on an individual basis.

## Recommendations

### I. Staging

Investigations may include

- History and clinical examination
- Cervical biopsy; an expert pathology review should be performed by a pathologist with experience in gynecologic pathology.
- Blood work (CBC, LFT, renal function studies)
- Imaging is optional for stage <IB1. For stage IB1 and higher, MRI is recommended; chest x-ray and PET-CT may be performed.
- Cone biopsy, as indicated

### II. Treatment

Consider enrollment in a clinical trial, if available. Up to date information on trials offered in Alberta is available on the [Alberta Cancer Clinical Trials](#) website.

**FIGO Stage IA1** (Level of Evidence: I Strength of Recommendation: A )<sup>5-7,13,17</sup>

Preferred options include:

- Invasive carcinoma <4 cm in greatest dimension
- Conization with free margins
- OR simple hysterectomy
- OR modified radical hysterectomy if there is multifocal invasion
- If there is lymphovascular space involvement, consider pelvic lymphadenectomy

### **FIGO Stage IA2**

Preferred options include:

- Invasive carcinoma  $\geq 4$  cm in greatest dimension
- Conization +/- pelvic lymphadenectomy (PLND) +/- para-aortic lymphadenectomy (PALND) +/- sentinel lymph node biopsy (SLNB)
- OR simple or modified radical hysterectomy +/- PLND +/- PALND +/- SLNB
- OR radical or simple trachelectomy for fertility preservation +/- PLND +/- PALND +/- SLNB

### Special Considerations

Radical or simple trachelectomy indications:

- Lesion  $\leq 2$  cm
- Preservation of fertility
- Small adenocarcinomas can be considered at physician discretion
- No lymphovascular invasion; limited endocervical involvement

SLNB indications:

- SLNB is recommended when performed at a centre with a validated technique

### **FIGO Stage IB1**

Preferred options include:

- Invasive carcinoma  $\geq 5.0$  mm depth of invasion and  $< 2.0$  cm in greatest dimension
- Radical hysterectomy + PLND +/- PALND +/- SLNB; adjuvant post-operative radiotherapy is considered only when adverse pathological findings are found
- OR pelvic RT + brachytherapy. This is usually considered for patients who are not candidates for surgery; although less evidence is available to support the addition of chemotherapy to primary RT for this subgroup, chemoradiation is the preferred option.
- OR radical or simple trachelectomy + PLND +/- PALND +/- SLNB could be considered for patients wishing fertility preservation

Post-operative adjuvant therapy guidelines as described below will be applied to this subgroup.

### **FIGO Stage IB2**

Preferred options include:

- Invasive carcinoma  $\geq 2.0$  cm and  $< 4.0$  cm in greatest dimension
- Pelvic RT + concurrent chemotherapy (cisplatin  $\times 5 - 6$  cycles) followed by brachytherapy. There is insufficient evidence to recommend upfront lymph node debulking.
- OR radical hysterectomy + PLND +/- PALND

### **FIGO Stage IB3:**

- Invasive carcinoma  $\geq 4$  cm in greatest dimension

- Pelvic RT + concurrent chemotherapy (cisplatin × 5 - 6 cycles) followed by brachytherapy. There is insufficient evidence to recommend upfront lymph node debulking.
- OR radical hysterectomy + PLND +/- PALND *in selected circumstances*

### **FIGO Stage IIA1**

- Invasive carcinoma <4.0 cm in greatest dimension

Preferred options include:

- Pelvic RT + concurrent chemotherapy (cisplatin × 5 - 6 cycles) followed by brachytherapy
- OR radical hysterectomy + PLND +/- PALND *in selected circumstances*

Neoadjuvant chemotherapy can be considered for this subgroup, but there is a lack of high quality evidence to support this as the standard of care.

Post-operative adjuvant therapy guidelines as described below will be applied to this subgroup.

### **FIGO Stage IIA2**

- Invasive carcinoma ≥4.0 cm in greatest dimension

Preferred options include:

- Pelvic RT + concurrent chemotherapy (cisplatin × 5 - 6 cycles) followed by brachytherapy. There is insufficient evidence to recommend upfront lymph node debulking.
- OR radical hysterectomy + PLND +/- PALND *in selected circumstances*

Neoadjuvant chemotherapy can be considered for this subgroup, but there is a lack of high quality evidence to support this as the standard of care.

Post-operative adjuvant therapy guidelines as described below will be applied to this subgroup.

### **FIGO Stage IIB/IIIA/B/IV**

Options include:

- Medically fit patients: tailored EBRT + concurrent chemotherapy (cisplatin × 5-6 cycles) followed by brachytherapy, there is insufficient evidence to recommend upfront lymph node debulking
- Medically unfit patients: palliative or radical RT can be given at the discretion of the radiation oncologist

### Post-operative Adjuvant Therapy

1. Consider the following risk factors when deciding on appropriate treatment options: (*Level of Evidence: III Strength of Recommendation: C*)<sup>7,10</sup>.

- Histology (e.g. adenocarcinoma, adenosquamous versus squamous cell carcinoma)
- Tumour size

- Depth of stromal invasion
- Lymphovascular space invasion (LVSI)
- Nodal status
- Parametrial margin status
- Vaginal margin status

### Radiation Therapy

Radiation therapy should be administered as follows: (*Level of Evidence: IV Strength of Recommendation: D*)<sup>14</sup>

Pelvic RT: 45 – 50.4 Gy in 25 – 28 fractions (1.8 to 2.0 Gy per fraction) over 5-5.5 weeks

- Intracavitary brachytherapy may include HDR or PDR techniques
- Boost to the parametria may be given as clinically indicated.

*Note: Patients should maintain adequate hemoglobin level during radiotherapy.*

### Special Clinical Scenarios

1. Adjuvant hysterectomy may be considered among patients in whom intracavitary insertion is unsuccessful after the initial chemoradiation, and the patient is unable to have brachytherapy (*Level of Evidence: IV Strength of Recommendation: D*)<sup>14</sup>
2. If intracavitary brachytherapy cannot be performed, and patient is not a surgical candidate, consider a smaller pelvic boost technique (e.g. 3D conformal or IMRT may be considered) (*Level of Evidence: I Strength of Recommendation: A*)<sup>15</sup>

### Adjuvant Chemotherapy

2. Cisplatin should be administered at a radiosensitizing dose of 40 mg/m<sup>2</sup> (max = 80) intravenously over one hour weekly for 5 - 6 cycles during EBR. (*Level of Evidence: II Strength of Recommendation: B*)<sup>17,10,33</sup>

### **Recurrent/Persistent Disease**

Investigations may include

- History and clinical examination
- Blood work (CBC, LFT, renal function studies)
- Imaging: chest x-ray; CT-PET chest, abdomen and pelvis, MRI of the pelvis

Treatment options for *curable* pelvic recurrence include:

- Radical RT, with or without cisplatin, for patients previously treated with surgery
- Pelvic exenteration, for patients previously treated with upfront radical RT

Treatment for *incurable* pelvic recurrence may include palliative RT and chemotherapy.

Treatment options for extra-pelvic recurrences include:

- Clinical trial
- Palliative chemotherapy
- Palliative RT

### III. Follow Up and Surveillance

The following recommendations have been modified from the Cancer Care Ontario <sup>12</sup> follow-up guidelines:

- Inform patients about symptoms of recurrence.
- For the first two years, patients should be followed closely by a physician experienced in the surveillance of cancer; follow-up visits should be held every 3 to 4 months within the first two years.
- After the first two years, the patient can be discharged to the primary care physician; follow-up visits should be held annually and should include annual cytology.
- Follow-up visits should include a history (e.g. any symptoms elicited) and complete physical examination (including a speculum exam with bimanual and pelvic/rectal examination).
- There is little evidence to suggest that vaginal vault cytology more than once a year is useful.

Vaginal or cervical vault cytology examination is recommended annually except in patients treated with radiotherapy; there is little evidence to support the routine use of vaginal or cervical vault cytology in patients treated with radiotherapy. Pap smears are not substitute for a careful pelvic examination (*Level of Evidence: II Strength of Recommendation: B*) <sup>9,10,12</sup>.

## Discussion

### Primary Therapy

Early stage cervical cancer is usually treated with either surgery or radiotherapy alone depending on age and other patient factors. Adjuvant postoperative radiotherapy is considered only when adverse pathological findings are found. Observation may be an option for select stage IA1 patients, if fertility is to be preserved <sup>8</sup>. Surgery alone is generally reserved for stage IA1, IA2, and IB1 patients <sup>7,13</sup>. Surgical procedures include cone biopsy, trachelectomy or simple or modified radical hysterectomy, with or without pelvic lymphadenectomy. Pelvic lymphadenectomy should be mainly used in stage IB disease or higher, as lymph node metastases occurs in only 0.5% of stage IA2 patients <sup>17</sup>. Radical or simple trachelectomy may be used for stage IB1 if the lesion is < 2 cm, there is no lymphovascular space invasion, and preservation of fertility is desired. In a randomized controlled trial setting, preoperative intracavity high dose rate brachytherapy (HDR-BT; 2x8 Gy) plus radical surgery was compared with no preoperative treatment plus radical surgery in operable FIGO stage IA2-IIB patients; the pathological complete response rate was significantly higher (26.8% [11/41] vs. 7.1% [3/42]; p = 0.0204) in the preoperative BT group <sup>18</sup>.

Medically fit patients with advanced stage cervical cancer (stage IB2/IIB/IIIA/IIIB/IVA), as well as select stage IIA cases, should be considered for treatment with concurrent radiotherapy and chemotherapy <sup>7, 8, 10, 13</sup>. A meta-analysis of 13 trials showed that chemoradiotherapy (versus radiotherapy alone) increased the disease free survival rate at five years by eight percent <sup>16</sup>. There was a significant trend towards increased overall survival with decreasing stage of disease ( $p = 0.017$ ), with stage IA/IB/IIA patients achieving the lowest hazard ratio for death. In 1999 a clinical alert was communicated supporting the use of concurrent chemotherapy in locally advanced cervix cancer patients. One of the trials forming this alert had included PA node radiation as part of its control arm. Given that the chemotherapy experimental arm achieved superior survival it is recommended that routine PA node radiotherapy no longer be applied to this subgroup of patients. Medically unfit patients may be treated with palliative radiotherapy given at the discretion of the radiation oncologist <sup>7</sup>. For distant metastases, systemic therapy or individualized radiotherapy could be offered.

Radiation therapy should be administered as 45 – 50.4 Gy in 25 – 28 fractions (1.8 - 2.0 Gy per fraction) over five to five and a half weeks. The addition of intracavitary brachytherapy may include HDR or PDR techniques. A boost to the parametria can be given (usually 1.8 to 2.0 Gy per fraction) over three to five fractions, as clinically indicated. If brachytherapy is technically not feasible, then an external beam boost can be given using conformal radiotherapy or intensity modulated radiotherapy. For patients in whom intracavitary insertion is unsuccessful after the initial treatment with chemoradiation, an adjuvant hysterectomy may be considered. A recent retrospective analysis showed that, in this setting, adjuvant hysterectomy (versus further pelvic external beam radiotherapy) was associated with a nonsignificant decrease in the rate of relapse (0 patients, 0% vs. 7 patients, 50%;  $p=0.068$ ) and the rate of death from recurrent disease (0 patients, 0% vs. 6 patients, 43%;  $p = 0.152$ ) after 63 months of follow up <sup>14</sup>. Radio-therapy to the PA lymph nodes is also suggested if there is known to be radiological or identified pathologic involvement of the common iliac chain or PA nodes. Such treatment can be delivered synchronously with the pelvic RT, but where patients are receiving cisplatin based chemotherapy it will likely be necessary to delay the PA lymph node treatment until after the pelvic treatment. There is minimal evidence to drive practice in this area.

The optimal regimen for concurrent chemoradiation has not yet been defined; however, cisplatin-based concurrent chemoradiation has been used in several trials <sup>19-21</sup>, including three Gynecologic Oncology Group Trials <sup>22-24</sup> that showed a significant benefit of chemoradiation versus radiotherapy alone. The most common regimen used in these trials was cisplatin at a dose of 40 mg/m<sup>2</sup> intravenously over one hour weekly for five to six cycles. Carboplatin is recommended if patient is intolerant to cisplatin containing chemoradiation <sup>7</sup>.

Upfront lymph node debulking has been proposed for patients with locally advanced stage cervical cancer to improve treatment planning and possible therapeutic benefit. However, there is insufficient evidence to recommend this procedure. A Cochrane review identified one trial investigating



pretreatment lymph node dissection for surgical staging and was therefore unable to provide specific conclusions on the effectiveness of this treatment and recommended individualized treatment <sup>25</sup>.

There is a growing evidence that sentinel lymph node biopsy (SLNB) for nodal staging is useful for decreasing the need for pelvic lymphadenectomy in patients with early stage cervical cancer. Nodal stage is an important predictor of prognosis that can be used to guide treatment decisions <sup>26,27</sup>. Furthermore, SLNB may reduce the need for a lymphadenectomy, which is associated with complications such as lymphedema <sup>28</sup>. The feasibility of this procedure is demonstrated by a 2013 meta-analysis that included 17 studies with 1112 patients receiving SLNB <sup>29</sup>. The authors reported a pooled detection rate of 92.2%, sensitivity of 88.8%, negative predictive value of 95% and the results improved when limited to tumours  $\leq 2$  cm. An additional meta-analysis including 67 studies conducted in 2014 found similar results; a pooled sentinel node detection rate of 89.2% and sensitivity of 90% <sup>30</sup>. In particular, the SENTICOL multicenter prospective study (n = 139 with stage IA1 or IB1 cervical cancer) found SLNB (with intracervical injection of radiocolloid and blue dye) is able to detect unusual drainage pathways and micrometastases resulting in improved nodal staging; detection rate of 97.8%, sensitivity of 92% and two false-negative results <sup>31</sup>. Although research shows the value of SLNB there is currently no standard protocol for conducting the procedure. There are various surgical techniques including the use of blue dye, radioisotope or a combination of the two and whether pathological ultrastaging of dissected nodes is completed. However based on the recent metaanalysis, Indocyanin green dye (ICG) showed similar overall and bilateral detection rate as dual blue dye/technetium-99 <sup>32</sup>. Another Phase III FILM trial also demonstrated that ICG tracer identified more SLNs as compared to blue dye <sup>33</sup>. Cormier and colleagues proposed an algorithm for SLNB, which was included in the NCCN guideline <sup>34</sup>. It suggests that all mapped sentinel nodes be excised and ultrastaged, all suspect nodes be removed regardless of mapping, if only unilateral mapping performed then contralateral lymph node dissection be performed, all procedures include parametrectomy en bloc with primary tumor resection. The authors evaluated this algorithm in 122 patients and were able to identify 100% of positive lymph nodes. However, the value of identifying micrometastases by ultrastaging is not clear.

## Adjuvant Therapy

Following radical hysterectomy, the type of adjuvant therapy will depend on the patient's risk factors. Factors to consider include histology, tumour size, depth of stromal invasion, lymphovascular space invasion (LVSI), nodal status, parametrial margin, and vaginal margin. Patients with a negative nodal status, negative parametrial margins, and negative vaginal margins are considered low risk; for these patients, observation following surgery is an acceptable option <sup>7,13</sup>.

Patients are considered intermediate risk for relapse if they exhibit any of the following: squamous cell carcinoma, adenocarcinomas or adenosquamous carcinomas with any two of the following risk

factors; tumour size between 2 - 5 with over 1/3rd deep, middle or superficial invasion and positive LVSI; or any tumour size  $\geq 4$  cm with over 1/3rd middle or deep invasion and negative LVSI <sup>7</sup>. Whole pelvic radiotherapy with or without weekly cisplatin (6 cycles) should be considered for intermediate risk patients. For patients with adenocarcinoma or adenosquamous tumour plus one risk factor, there is uncertainty on the benefits of chemoradiation. A discussion with the radiation oncologist regarding the benefit of chemoradiotherapy may be required <sup>7,10</sup>. Follow up of a phase III randomized (Gynecologic Oncology Group) trial showed that among patients with stage IB cervical cancer with negative lymph nodes but with two or more of the following:  $> 1/3^{\text{rd}}$  (deep) stromal invasion, capillary lymphatic space involvement, or  $\geq 4$  cm tumour diameter, postoperative external-beam irradiation to the standard pelvic field improved survival versus radical hysterectomy and pelvic lymphadenectomy alone (observation). There were 27 deaths among the radiotherapy group versus 40 deaths in the observation group (overall survival HR was 0.70, 90% CI 0.45-1.05,  $p = 0.074$ ) <sup>10,33</sup>. A Cochrane Collaboration meta-analysis in 2009 found no significant difference in survival among patients who received adjuvant radiation or no further treatment, at five years (RR 0.8; 95% CI 0.3-2.4); however, patients who received radiation had a significantly lower rate of progression (RR 0.6; 95% CI 0.4-0.5), as compared to those with no further treatment <sup>19</sup>.

Patients are considered high risk for relapse if they exhibit positive pelvic nodes and/or positive margins. These patients should be treated with whole pelvic radiotherapy with or without brachytherapy plus weekly cisplatin for six cycles <sup>7,13</sup>.

Neoadjuvant chemotherapy has been proposed for locally advanced cervical cancer. Several reviews have examined the use of neoadjuvant chemotherapy for cervical cancer, however, they have not compared this treatment to current standard practice of chemoradiation <sup>36-38</sup>. In particular, a 2013 meta-analysis comparing neoadjuvant chemotherapy and surgery vs. primary surgery, in five trials, found reduced rates of large tumour size, lymph node metastasis, need of adjuvant radiation therapy, distant metastases, but no difference in recurrence, progression free survival and overall survival <sup>38</sup>. There is a lack of conclusive evidence for the benefit of neoadjuvant chemotherapy. A multi-centre phase III trial (EORTC55994) investigated the use of neoadjuvant chemotherapy prior to surgery compared to current practice of cisplatin-based chemoradiation. The results of this trial revealed no difference in 5-year OS between NACTS and CCRT, indicating that quality of life and long-term toxicity are important to decide optimal treatment. <sup>39</sup>

## Management of Recurrent Disease

Treatment of cervical cancer recurrence is directed by whether disease is confined to the pelvis or disseminated to extra-pelvic organs. Patients with curable pelvic recurrences are treated with radical radiotherapy, with or without cisplatin, if previously treated with surgery. If previously treated with radical radiotherapy then pelvic exenteration is considered <sup>40</sup>. Patients with incurable or extra-pelvic recurrences are offered enrolment in a clinical trial or treated with palliative chemotherapy and/or

radiotherapy.

Recommended chemotherapy includes single agent cisplatin as most effective agent. However carboplatin is recommended for the cisplatin intolerant patients <sup>7</sup>. First-line Combination chemotherapy can also be offered. The Gynecologic Oncology Group and others <sup>7,11,37,38</sup> have recommended the combination of cisplatin with paclitaxel and bevacizumab; or carboplatin with combination of paclitaxel and bevacizumab for the first-line combination therapy. A randomized phase III study showed a higher response rate and improved PFS with the combination of cisplatin/paclitaxel as compared to only cisplatin <sup>41</sup>. Another recent phase III trial showed the improvement in OS with combination of cisplatin/paclitaxel/bevacizumab <sup>42</sup>.

Pembrolizumab has been approved by the FDA in the USA as second-line therapy for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS)  $\geq 1$ ]. However it has not as yet received approval in Canada <sup>43</sup>. In a phase III clinical trial among patients with advanced or recurrent stage IVB cervical cancer (n = 513), the combination of paclitaxel and cisplatin outperformed the combinations of vinorelbine and cisplatin, gemcitabine and cisplatin, and topotecan and cisplatin in terms of overall response rate (29.1% vs. 25.9% vs. 22.3% vs. 23.4%, respectively) and was not inferior in terms of risk of progression or risk of death <sup>44,45</sup>. Similar response rates have been reported elsewhere <sup>46</sup>. Phase II clinical trial data suggests that the addition of ifosamide to cisplatin and paclitaxel may be more effective for recurrent or metastatic disease; among 153 patients treated with either this triplet combination or with ifosamide and cisplatin, the overall response rates were 59% and 33%, respectively (p < 0.01). Furthermore, progression free and overall survival times were significantly longer among patients who received the triplet regimen (7.9 vs. 6.3 months and 15.4 vs. 13.2 months, respectively) <sup>47</sup>.

## Follow Up and Surveillance

There are no randomized controlled trials to inform best practice for the follow up of patients with cervical cancer; rather, recommendations are based on data from retrospective studies. Given that the majority (62 to 89%) of cervical cancer recurrences are detected within two years and nearly all (89 to 99%) are detected within five years <sup>48</sup>, the most rigorous follow up should be done during the first five years following treatment <sup>12</sup>. A systematic review of 13 trials showed that vaginal vault cytology detected asymptomatic recurrent disease in only 0 to 17% of patients, whereas asymptomatic recurrent disease was detected using physical exam in 29 to 71% of patients <sup>48</sup>. Therefore, vaginal vault cytology may be warranted once yearly only.

## References

1. Canadian Cancer Statistics Advisory Committee [Internet]. Canadian Cancer Statistics 2018 Toronto, ON: Canadian Cancer Society; 2018. Available at: [www.cancer.ca/Canadian-Cancer-Statistics-2018-EN](http://www.cancer.ca/Canadian-Cancer-Statistics-2018-EN) (accessed March 2019).
2. Surveillance & Reporting. 2019 Report on Cancer Statistics in Alberta. Edmonton: CancerControl AB, Alberta Health Services; 2015.
3. Chuang T L, Temin S, Camacho R, et al. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. *J Glob Oncol*. 2016 Oct; 2(5): 311–340 PMID: 28717717
4. Bray F, Ferlay J, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Cancer J Clin* 2018 Nov;68(6):394-424 PubMed ID 31492677
5. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. *Int J Gynaecol Obstet*. 2019 Apr;145(1):129-135
6. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009 May;105(2):103-104 PubMed ID 19367689.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. ;Version 2.2020.
8. Marth C, Landoni F, Manher S et al. Cervical Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. *Ann Oncol*. 2017 Jul 1; 28 PMID: 28881916
9. BC Cancer Agency. Cancer Management Guidelines: Gynecology: Uterine Cervix: Management. Available at: [www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gynecology/UterineCervix1of2/default.htm](http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gynecology/UterineCervix1of2/default.htm). Accessed 05/3, 2018
10. Lukka H, Hirte H, Fyles A and members of the Gynecology Cancer Disease Site Group. Primary Treatment for Locally Advanced Cervical Cancer: Concurrent Platinum-based Chemotherapy and Radiation. Report #4-5, June 2004. Available at: <https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc4-5f.pdf>. Accessed 07/24, 2014.
11. Hirte H, Strychowsky J, Oliver T and the Gynecology Cancer Disease Site Group. Chemotherapy for recurrent, Metastatic, or Persistent Cervical Cancer: A Clinical Practice Guideline: A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO). Evidence-Based Series #4-20. Available at: <https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc4-20f.pdf>. Accessed 07/24, 2014.
12. Elit L, Kennedy EB, Fyles A, Metser U. Follow-up for Cervical Cancer. 2015 May 12;Program in Evidence-Based Care Guideline 4-16 Version 2.
13. Tom Baker Cancer Centre: Management of Gynecological Malignancies. 2008
14. Walji N, Chue AL, Yap C, Rogers LJ, El-Modir A, Chan KK, et al. Is there a role for adjuvant hysterectomy after suboptimal concurrent chemoradiation in cervical carcinoma? *Clin Oncol (R Coll Radiol)* 2010 Mar;22(2):140-146 PubMed ID 20045300.
15. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, Khorprasert C, Rojponpradit P, Chottetanaprasith T, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. *Int J Radiat Oncol Biol Phys* 2004 Aug 1;59(5):1424-1431 PubMed ID 15275728.
16. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. *J Clin Oncol* 2008 Dec 10;26(35):5802-5812 PubMed ID 19001332.
17. Rogers LJ, Luesley DM. Stage IA2 cervical carcinoma: how much treatment is enough? *Int J Gynecol Cancer* 2009 Dec;19(9):1620-1624 PubMed ID 19994472.
18. Vizkeleti J, Pete I, Vereczkey I, Frohlich G, Horvath K, Varga S, et al. Complete pathologic remission after preoperative high-dose brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized study. *Magy Onkol* 2012 Sep;56(3):171-177 PubMed ID 23008825.
19. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. *J Clin Oncol* 2002 Feb 15;20(4):966-972 PubMed ID 11844818.
20. Kantardzic N, Beslija S, Begic D. Comparative parameters of myelotoxicity in patients treated with simultaneous chemotherapy and radiotherapy or only radiotherapy. *Med Arh* 2004;58(1):19-22 PubMed ID 15017898.

21. Cikaric S, Petrovic-Stupar S, Marjanov I. Radiotherapy vs. radiotherapy + chemotherapy of advanced cervical cancer: Regression of tumour, early and late sequelaes, relapses of disease and 3 years survival (the third phase). Available at: <http://www.onk.ns.ac.rs/archive/vol13/PDFVol13/V13s1p34.pdf>. Accessed 07/24, 2014.
22. Keys HM, Bundy BN, Stehman FB, Okagaki T, Gallup DG, Burnett AF, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. *Gynecol Oncol* 2003 Jun;89(3):343-353 PubMed ID 12798694.
23. Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA, 3rd, Moore DH, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. *J Clin Oncol* 2005 Nov 20;23(33):8289-8295 PubMed ID 16230678.
24. Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007 Jul 1;25(19):2804-2810 PubMed ID 17502627.
25. Brockbank E, Kokka F, Bryant A, Pomel C, Reynolds K. Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. *Cochrane Database Syst Rev* 2013 Mar 28;3:CD008217 PubMed ID 23543561
26. Biewenga P, van der Velden J, Mol BW, Stalpers LJ, Schilthuis MS, van der Steeg JW, et al. Prognostic model for survival in patients with early stage cervical cancer. *Cancer* 2011 Feb 15;117(4):768-776 PubMed ID 20922801.
27. Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? *Gynecol Oncol* 2004 Feb;92(2):525-529 PubMed ID 14766243.
28. Matsuura Y, Kawagoe T, Toki N, Tanaka M, Kashimura M. Long-standing complications after treatment for cancer of the uterine cervix--clinical significance of medical examination at 5 years after treatment. *Int J Gynecol Cancer* 2006 Jan-Feb;16(1):294-297 PubMed ID 16445648
29. Wu Y, Li Z, Wu H, Yu J. Sentinel lymph node biopsy in cervical cancer: A meta-analysis. *Mol Clin Oncol* 2013 Nov;1(6):1025-1030 PubMed ID 24649288.
30. Kadkhodayan S, Hasanzadeh M, Treglia G, Azad A, Yousefi Z, Zarifmahmoudi L, et al. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. *Eur J Surg Oncol* 2015 Jan;41(1):1-20 PubMed ID 25454828.
31. Bats AS, Mathevet P, Buenerd A, Orliaguet I, Mery E, Zerdoud S, et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. *Ann Surg Oncol* 2013 Feb;20(2):413-422 PubMed ID 22911367.
32. Ruscito I, Gasparri L M, Braicu L E et al. Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis. *Ann Surg Oncol*. 2016 Oct;23(11):3749-3756 PMID: 27160526
33. Frumovitz M, Plante M, Lee S.P, et al. A randomized phase III multicenter study assessing near infrared fluorescence in the detection of sentinel lymph nodes in women with cervical and uterine cancers: the FILM Trial. *Lancet Oncol*. 2018 Oct; 19(10): 1394–1403. PMID: 30143441
34. Cormier B, Diaz JP, Shih K, Sampson RM, Sonoda Y, Park KJ, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. *Gynecol Oncol* 2011 Aug;122(2):275-280 PubMed ID 21570713.
35. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Mudderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. *Int J Radiat Oncol Biol Phys* 2006 May 1;65(1):169-176 PubMed ID 16427212.
36. Tierney J, Rydzewska L. Neoadjuvant chemotherapy for locally advanced cervix cancer. *Cochrane Database of Systematic Reviews* 2015;2.
37. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. *Cochrane Database Syst Rev* 2012 Dec 12;12:CD007406 PubMed ID 23235641.
38. Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. *Eur J Surg Oncol* 2013 Feb;39(2):115-124 PubMed ID 23084091
39. Kenter G, Greggi S, Vergote I et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. *JCO* V37-15 2019.
40. National Comprehensive Cancer Network. Guidelines and Clinical Resources: Cervical Cancer. V1.2016. Available at: <http://www.nccn.org>.
41. Moore KN, Herzog TJ, Lewin S et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. *Gynecol Oncol*. 2007 May;105(2):299-303. PMID: 17303230



42. Tiwari KS, Sill MW, Long HJ et al. Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study. *Lancet*. 2017 Oct 7; 390(10103): 1654–1663. PMID: 28756902
43. Stanger M. Pembrolizumab for Advanced Cervical Cancer Progressing During or After Chemotherapy. Sep 2018
44. Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, et al. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2010 Dec;119(3):531-537 PubMed ID 20837359.
45. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2009 Oct 1;27(28):4649-4655 PubMed ID 19720909.
46. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol* 2004 Aug 1;22(15):3113-3119 PubMed ID 15284262.
47. Moutzios G, Dimopoulos MA, Bamias A, Vourli G, Kalofonos H, Aravantinos G, et al. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. *Ann Oncol* 2009 Aug;20(8):1362-1368 PubMed ID 19457937.
48. Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M, Gynecology Cancer Disease Site Group. Follow-up for women after treatment for cervical cancer: a systematic review. *Gynecol Oncol* 2009 Sep;114(3):528-535 PubMed ID 19560188.

## Development and Revision History

This guideline was reviewed and endorsed by the Alberta GYNE Tumour Team. Members include [surgical oncologists, radiation oncologists, medical oncologists, dermatologists, nurses, pathologists, and pharmacists]. Evidence was selected and reviewed by a working group comprised of members from the Alberta Tumour Teams, external participants identified by the Working Group Lead, and a methodologist from the Guideline Resource Unit. A detailed description of the methodology followed during the guideline development process can be found in the [Guideline Resource Unit Handbook](#).

This guideline was originally developed in 2009 in 2011, 2012, 2013, 2015 and again in 2021

## Levels of Evidence

I	Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity
II	Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity
III	Prospective cohort studies
IV	Retrospective cohort studies or case-control studies
V	Studies without control group, case reports, expert opinion

## Strength of Recommendations

A	Strong evidence for efficacy with a substantial clinical benefit; strongly recommended
B	Strong or moderate evidence for efficacy but with a limited clinical benefit; generally recommended
C	Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.); optional
D	Moderate evidence against efficacy or for adverse outcome; generally not recommended
E	Strong evidence against efficacy or for adverse outcome; never recommended

## Maintenance

A formal review of the guideline will be conducted in 2022. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

## Abbreviations

CI, Confidence interval; EBRT, External beam radiotherapy; Gy, Gray; unit of radiation; HR, Hazard ratio; HDR, High dose rate; IMRT, Intensity modulated radiotherapy; LVSI, Lymphovascular space involvement; PA, Para-aortic; PDR, Pulsed dose rate; PALND, Para-aortic lymphadenectomy; PLND, Pelvic lymphadenectomy; RT, Radiotherapy, RR, Relative risk; SLNB, Sentinel lymph node biopsy

## Disclaimer

The recommendations contained in this guideline are a consensus of the Alberta Provincial GYNE Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

## Copyright © (2021) Alberta Health Services

This copyright work is licensed under the [Creative Commons Attribution-NonCommercial-NoDerivative 4.0 International license](#). You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and abide by the other license terms. To view a copy of this license, see <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

## Funding Source

Financial support for the development of CancerCare Alberta's evidence-based clinical practice guidelines and supporting materials comes from the CancerCare Alberta operating budget; no outside commercial funding was received to support the development of this document.

All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the [Outpatient Cancer Drug Benefit Program Master List](#).

## Conflict of Interest Statements

Dr. **Prafull Ghatage** has nothing to disclose.  
Dr. **Gregg Nelson** has nothing to disclose.  
Dr. **Helen Steed** has nothing to disclose.  
**Ritu Sharma** has nothing to disclose.